Overview

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Status:
NOT_YET_RECRUITING

Trial end date:
2029-05-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Phase:

PHASE3

Details

Lead Sponsor:

Incyte Corporation

Collaborators:

ENGOT Foundation
GOG Foundation

Treatments:

Gemcitabine
liposomal doxorubicin
Paclitaxel
Topotecan